Company / Profit Margin
Viridian Therapeutics, Inc.\DE Profit Margin History
FY2016-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-5738.5%
FY2017
5-year range
-
FY2016-FY2017
Trend
-1055.1%
vs FY2016
Sector context
#142 of 146
Health Care
What the data says
Among 146 Health Care companies, Viridian Therapeutics, Inc.\DE is in the bottom 3% for profit margin.
Based on SEC 10-K filings.
-5738.5% in FY2017.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 146This company -5738.5% Sector average -796.3%
▼
-620.7% below sector average
Key checks
Key Insights
- In FY2017, profit margin decreased 1055.1% year-over-year.
- Currently 4942.3pp below the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | -5738.5% | -1055.1% |
| FY2016 | -496.8% | -150.2% |
As of FY2017 · SEC 10-K · Updated Jun 30, 2026